Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A TWINSS extension trial to evaluate the safety and tolerability of CFZ533 (iscalimab) at two dose levels administered subcutaneously in patients with Sjögren’s Syndrome

    Summary
    EudraCT number
    2020-001942-20
    Trial protocol
    HU   GR   DE   PT   FR   NL   IT   SE  
    Global end of trial date
    19 Aug 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    28 Jun 2025
    First version publication date
    28 Jun 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CCFZ533B2201E1
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04541589
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Novartis Pharma AG
    Sponsor organisation address
    Novartis Campus,, Basel, Switzerland,
    Public contact
    Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com
    Scientific contact
    Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    19 Aug 2024
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    19 Aug 2024
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of this study is to evaluate the safety and tolerability of iscalimab at two dose levels (600 mg and 300 mg) in patients with Sjögren’s Syndrome, who participated in the TWINSS core study (CCFZ533B2201)
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    05 Jan 2021
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Argentina: 5
    Country: Number of subjects enrolled
    Australia: 1
    Country: Number of subjects enrolled
    Austria: 11
    Country: Number of subjects enrolled
    Brazil: 8
    Country: Number of subjects enrolled
    Canada: 5
    Country: Number of subjects enrolled
    Chile: 21
    Country: Number of subjects enrolled
    Colombia: 7
    Country: Number of subjects enrolled
    France: 7
    Country: Number of subjects enrolled
    Germany: 19
    Country: Number of subjects enrolled
    Greece: 2
    Country: Number of subjects enrolled
    Hungary: 12
    Country: Number of subjects enrolled
    Israel: 7
    Country: Number of subjects enrolled
    Italy: 2
    Country: Number of subjects enrolled
    Japan: 14
    Country: Number of subjects enrolled
    Korea, Republic of: 5
    Country: Number of subjects enrolled
    Netherlands: 8
    Country: Number of subjects enrolled
    Portugal: 9
    Country: Number of subjects enrolled
    Romania: 6
    Country: Number of subjects enrolled
    Russian Federation: 30
    Country: Number of subjects enrolled
    Sweden: 1
    Country: Number of subjects enrolled
    Türkiye: 3
    Country: Number of subjects enrolled
    United Kingdom: 7
    Country: Number of subjects enrolled
    United States: 16
    Worldwide total number of subjects
    206
    EEA total number of subjects
    77
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    171
    From 65 to 84 years
    35
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Participants who completed the core study (CCFZ533B2201, NCT03905525) and were deemed by the Investigator to clinically benefit from continued iscalimab therapy based upon response to therapy at the end of the treatment period of the core study were enrolled in this study

    Period 1
    Period 1 title
    Treatment period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Carer, Data analyst, Assessor
    Blinding implementation details
    The study was conducted as a double-blind treatment until the final database lock of the Core study (NCT03905525). During this period, participants, Investigator, site staff, and persons performing the assessments remained blinded to the identity of the treatment until the final database lock of the core study

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Arm 1: Iscalimab 600 mg
    Arm description
    Participants received 600 mg (2 injections of 300 mg/2 mL) of iscalimab subcutaneously weekly for the initial 3 weeks as loading doses, followed by a bi-weekly maintenance regimen at 600 mg (2 injections of 300 mg/2 mL).
    Arm type
    Experimental

    Investigational medicinal product name
    Iscalimab
    Investigational medicinal product code
    CFZ533
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Iscalimab 600 mg or 300 mg was administered subcutaneously weekly for the first 3 weeks. Subsequently, iscalimab was administered subcutaneously bi-weekly (every other week or Q2W).

    Arm title
    Arm 2 - Iscalimab 300 mg
    Arm description
    Participants received one dose of 600 mg (2 injections of 300 mg/2 mL) of iscalimab subcutaneously on the first day of the extension study; then 300 mg weekly (1 injection of 300 mg/2 mL of iscalimab and 1 injection of 2 mL of placebo) for the next 2 weeks as loading doses. This was followed by a bi-weekly maintenance regimen of 300 mg (1 injection of 300 mg/2 mL of iscalimab and 1 injection of 2 mL of placebo). After the final database lock of the core study, participants underwent unblinding, leading to the discontinuation of placebo injections.
    Arm type
    Experimental

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder and solvent for solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Placebo (1 injection of 2 ml) administered to participants in the iscalimab 300 mg arm to mantain blinding until the final database lock of the core study

    Investigational medicinal product name
    Iscalimab
    Investigational medicinal product code
    CFZ533
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Iscalimab 600 mg or 300 mg was administered subcutaneously weekly for the first 3 weeks. Subsequently, iscalimab was administered subcutaneously bi-weekly (every other week or Q2W).

    Number of subjects in period 1
    Arm 1: Iscalimab 600 mg Arm 2 - Iscalimab 300 mg
    Started
    152
    54
    Completed
    133
    47
    Not completed
    19
    7
         Physician decision
    3
    1
         Consent withdrawn by subject
    1
    -
         Adverse event, non-fatal
    8
    2
         Subject decision
    7
    4

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Arm 1: Iscalimab 600 mg
    Reporting group description
    Participants received 600 mg (2 injections of 300 mg/2 mL) of iscalimab subcutaneously weekly for the initial 3 weeks as loading doses, followed by a bi-weekly maintenance regimen at 600 mg (2 injections of 300 mg/2 mL).

    Reporting group title
    Arm 2 - Iscalimab 300 mg
    Reporting group description
    Participants received one dose of 600 mg (2 injections of 300 mg/2 mL) of iscalimab subcutaneously on the first day of the extension study; then 300 mg weekly (1 injection of 300 mg/2 mL of iscalimab and 1 injection of 2 mL of placebo) for the next 2 weeks as loading doses. This was followed by a bi-weekly maintenance regimen of 300 mg (1 injection of 300 mg/2 mL of iscalimab and 1 injection of 2 mL of placebo). After the final database lock of the core study, participants underwent unblinding, leading to the discontinuation of placebo injections.

    Reporting group values
    Arm 1: Iscalimab 600 mg Arm 2 - Iscalimab 300 mg Total
    Number of subjects
    152 54 206
    Age Categorical
    Units: Participants
        <=18 years
    0 0 0
        Between 18 and 65 years
    126 45 171
        >=65 years
    26 9 35
    Sex: Female, Male
    Units: Participants
        Female
    148 53 201
        Male
    4 1 5
    Race/Ethnicity, Customized
    Units: Subjects
        White
    125 45 170
        Black or African American
    5 2 7
        Asian
    16 6 22
        American Indian or Alaska Native
    4 1 5
        Unknown
    2 0 2

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Arm 1: Iscalimab 600 mg
    Reporting group description
    Participants received 600 mg (2 injections of 300 mg/2 mL) of iscalimab subcutaneously weekly for the initial 3 weeks as loading doses, followed by a bi-weekly maintenance regimen at 600 mg (2 injections of 300 mg/2 mL).

    Reporting group title
    Arm 2 - Iscalimab 300 mg
    Reporting group description
    Participants received one dose of 600 mg (2 injections of 300 mg/2 mL) of iscalimab subcutaneously on the first day of the extension study; then 300 mg weekly (1 injection of 300 mg/2 mL of iscalimab and 1 injection of 2 mL of placebo) for the next 2 weeks as loading doses. This was followed by a bi-weekly maintenance regimen of 300 mg (1 injection of 300 mg/2 mL of iscalimab and 1 injection of 2 mL of placebo). After the final database lock of the core study, participants underwent unblinding, leading to the discontinuation of placebo injections.

    Primary: Number of participants with Treatment-emergent adverse events (TEAEs)

    Close Top of page
    End point title
    Number of participants with Treatment-emergent adverse events (TEAEs) [1]
    End point description
    An AE was defined as any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a participant. TEAE included all AEs up to the last dose date plus 14 weeks or the end of the entire study (including the safety follow-up period), whichever occurred earlier. A patient with multiple severity ratings for an AE was only counted under the maximum rating. Additionally, a patient with multiple occurrences of an event was counted only once. The severity of AEs was assessed using the Common Terminology Criteria for Adverse Events, with the following grading system: Mild: usually transient in nature and generally not interfering with normal activities; Moderate: sufficiently discomforting to interfere with normal activities; Severe: prevented normal activities. A serious adverse event (SAE) was defined as any AE that required medical intervention, hospitalization, or results in death, disability, or a birth defect.
    End point type
    Primary
    End point timeframe
    From start of extension study up to 14 weeks after last study-drug administration or end of study (whichever occurred earlier), assessed up to approximately 60 weeks
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analyses were planned for this primary end point.
    End point values
    Arm 1: Iscalimab 600 mg Arm 2 - Iscalimab 300 mg
    Number of subjects analysed
    152
    54
    Units: Participants
        Death
    0
    0
        AE (all severities)
    127
    43
        AE- Mild
    57
    24
        AEt- Moderate
    62
    17
        AE- Severe
    8
    2
        SAE
    13
    2
        AE leading to treatment discontinuation
    8
    2
    No statistical analyses for this end point

    Secondary: Free iscalimab concentration in plasma

    Close Top of page
    End point title
    Free iscalimab concentration in plasma
    End point description
    Free iscalimab concentration in plasma during the treatment (Ctrough) and follow-up (up to end of study) periods. Blood sample was collected at the specified timepoints to assess the concentration of free iscalimab. The baseline assessment of this extension study (Day 1) was identical to the last timepoint (FUP3/Week 60) of the core study (CCFZ533B2201).
    End point type
    Secondary
    End point timeframe
    Predose at Day 1, 113, 225, 337 and 421
    End point values
    Arm 1: Iscalimab 600 mg Arm 2 - Iscalimab 300 mg
    Number of subjects analysed
    149
    52
    Units: microgram / mililiter
    geometric mean (geometric coefficient of variation)
        Day 1
    3.56 ( 372.2 )
    451.8 ( 0.751 )
        Day 113
    125 ( 62.7 )
    56.9 ( 54.0 )
        Day 225
    126 ( 104.7 )
    50.3 ( 57.0 )
        Day 337
    138 ( 69.3 )
    62.6 ( 63.3 )
        Day 421
    4.47 ( 533.7 )
    350.4 ( 0.336 )
    No statistical analyses for this end point

    Secondary: Incidence of anti-iscalimab antibodies in plasma

    Close Top of page
    End point title
    Incidence of anti-iscalimab antibodies in plasma
    End point description
    Number of participants with anti-iscalimab antibodies (ADA) in plasma at any time during the study. The baseline assessment of this extension study (Day 1) was identical to the last timepoint (FUP3/Week 60) of the core study (CCFZ533B2201).
    End point type
    Secondary
    End point timeframe
    60 weeks
    End point values
    Arm 1: Iscalimab 600 mg Arm 2 - Iscalimab 300 mg
    Number of subjects analysed
    152
    54
    Units: Participants
    1
    2
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From start of extension study up to 14 weeks after last study-drug administration or end of study (whichever occurred earlier), assessed up to approximately 60 weeks
    Adverse event reporting additional description
    Any sign or symptom that occurred during the conduct of the trial and safety follow-up. The safety analyses were done on the safety population, which included all randomized subjects who received at least one dose of study medication. Patients were analyzed according to the actual treatment received.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    27.0
    Reporting groups
    Reporting group title
    Arm 2 - Iscalimab 300 mg
    Reporting group description
    Participants received one dose of 600 mg (2 injections of 300 mg/2 mL) of iscalimab subcutaneously on the first day of the extension study; then 300 mg weekly (1 injection of 300 mg/2 mL of iscalimab and 1 injection of 2 mL of placebo) for the next 2 weeks as loading doses. This was followed by a bi-weekly maintenance regimen of 300 mg (1 injection of 300 mg/2 mL of iscalimab and 1 injection of 2 mL of placebo). After the final database lock of the core study, participants underwent unblinding, leading to the discontinuation of placebo injections.

    Reporting group title
    Arm 1: Iscalimab 600 mg
    Reporting group description
    Participants received 600 mg (2 injections of 300 mg/2 mL) of iscalimab subcutaneously weekly for the initial 3 weeks as loading doses, followed by a bi-weekly maintenance regimen at 600 mg (2 injections of 300 mg/2 mL).

    Serious adverse events
    Arm 2 - Iscalimab 300 mg Arm 1: Iscalimab 600 mg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 54 (3.70%)
    13 / 152 (8.55%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Breast cancer
         subjects affected / exposed
    1 / 54 (1.85%)
    0 / 152 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Invasive ductal breast carcinoma
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Nervous system disorders
    Status epilepticus
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    Febrile neutropenia
         subjects affected / exposed
    0 / 54 (0.00%)
    2 / 152 (1.32%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Granulocytopenia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Neutropenia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Immune system disorders
    Food allergy
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Eye disorders
    Glaucoma
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Gastrointestinal disorders
    Anal prolapse
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholangitis
         subjects affected / exposed
    1 / 54 (1.85%)
    0 / 152 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pleurisy
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Psychiatric disorders
    Adjustment disorder with depressed mood
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Depression
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Sjogren's syndrome
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Infections and infestations
    Bartholinitis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    COVID-19
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    COVID-19 pneumonia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 152 (0.66%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Arm 2 - Iscalimab 300 mg Arm 1: Iscalimab 600 mg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    38 / 54 (70.37%)
    102 / 152 (67.11%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    3 / 54 (5.56%)
    9 / 152 (5.92%)
         occurrences all number
    3
    13
    Blood and lymphatic system disorders
    Neutropenia
         subjects affected / exposed
    2 / 54 (3.70%)
    10 / 152 (6.58%)
         occurrences all number
    3
    16
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    2 / 54 (3.70%)
    8 / 152 (5.26%)
         occurrences all number
    4
    13
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    4 / 54 (7.41%)
    13 / 152 (8.55%)
         occurrences all number
    4
    16
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    4 / 54 (7.41%)
    9 / 152 (5.92%)
         occurrences all number
    5
    11
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    5 / 54 (9.26%)
    9 / 152 (5.92%)
         occurrences all number
    7
    13
    Back pain
         subjects affected / exposed
    3 / 54 (5.56%)
    5 / 152 (3.29%)
         occurrences all number
    3
    6
    Osteoarthritis
         subjects affected / exposed
    3 / 54 (5.56%)
    7 / 152 (4.61%)
         occurrences all number
    3
    7
    Infections and infestations
    Influenza
         subjects affected / exposed
    7 / 54 (12.96%)
    7 / 152 (4.61%)
         occurrences all number
    7
    9
    Nasopharyngitis
         subjects affected / exposed
    9 / 54 (16.67%)
    22 / 152 (14.47%)
         occurrences all number
    17
    32
    Oral herpes
         subjects affected / exposed
    3 / 54 (5.56%)
    7 / 152 (4.61%)
         occurrences all number
    6
    13
    COVID-19
         subjects affected / exposed
    16 / 54 (29.63%)
    39 / 152 (25.66%)
         occurrences all number
    22
    46
    Sinusitis
         subjects affected / exposed
    3 / 54 (5.56%)
    7 / 152 (4.61%)
         occurrences all number
    5
    8
    Upper respiratory tract infection
         subjects affected / exposed
    5 / 54 (9.26%)
    19 / 152 (12.50%)
         occurrences all number
    5
    26
    Urinary tract infection
         subjects affected / exposed
    5 / 54 (9.26%)
    16 / 152 (10.53%)
         occurrences all number
    6
    23

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    17 Feb 2021
    The main purpose of the amendment was to include an additional assessment time point as part of the IRT algorithm criteria for participant rollover from the TWINSS core study (CCFZ533B2201) to extension study. ESSDAI and ESSPRI scores at Week 0 might be used for the IRT algorithm in the absence of a score at Week 4 of the core study. Specific guidance concerning public health emergency situations as declared by local or regional authorities (i.e., pandemic, epidemic or natural disaster) was also included.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jul 01 14:33:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA